> Cepheid ($CPHD) got an FDA nod for expanded claims for its Xpert tuberculosis test to remove patients from respiratory isolation. Release
> Invitae priced its IPO of 6,350,000 shares of common stock at an initial offering price of $16 per share, for total gross proceeds of $101.6 million. The company said it plans to trade on the NYSE under the symbol "NVTA." Statement
> France's Genomic Vision extended its collaboration with Quest Diagnostics ($DGX) through November 2018 to develop its molecular combing technology and market its molecular diagnostic tests. More
> Signal Genetics ($SGNL) priced an underwritten public offering of 3,214,285 shares of common stock at an offering price of $2.80 per share, expecting about $9 million from the offering. Release
> Swiss molecular diagnostics outfit Novigenix bought Colox, a new molecular blood test for colorectal cancer and pre-cancerous lesions, for an undisclosed sum. Statement
> Gaithersburg, MD-based Seegene scored an FDA OK for its herpes simplex virus molecular test. More
> Genomics outfit RainDance Technologies filed an infringement suit against California's 10X Genomics over patents RainDance exclusively licensed from the University of Chicago. Statement
And Finally… Harvard and MIT researchers are developing a rapid test that can identify deadly pathogens in less than 30 minutes and can be used as a point-of-care diagnostic tool. Story